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Queneau, Mohamed Guernou
Centre Cardiologique du Nord, Imagerie Scintigraphique, Saint Denis, France
Background: Myocardial perfusion imaging is an essential tool for man-
agement of coronary artery disease but leads to relative high radiation expo-
sure (average: 20 mSv, Berrington de Gonzalez, Circulation 2010) and
contributes up to 20% of the estimated annual collective radiation dose. We
previously published validation of new CZT cardiac cameras, improvement of
diagnosis performances and reduction of dosimetry lower than 10 mSv with
thallium (JESFC 2011).
Objectives: We used new cardiac CZT cameras to decrease to only 1 mSv
the effective dose with technetium agents. 
Methods: We prospectively studied 100 consecutive patients without pre-
viously known coronary artery disease referred for diagnostic stress myocar-
dial perfusion imaging. We injected at stress a low dose of Tc99m-sestaMIBI
(1.75 MBq/kg), performed immediate stress myocardial scan in 10 mn with a
CZT camera GE DNM 530c. We practiced rest myocardial scan 4 hours later
only when stress images were abnormal, with injection of a treble activity.
Results: Patients were 59 males and 41 females.There weight was 78±15
kg. They received at stress 135±30 MBq of Tc99m-sestaMIBI. Total and
myocardial acquired counts were 1092±308 kcts and 317±91 kcts. Quality of
scan was excellent in 82 cases and acceptable in other cases. The results were
normal in 90 cases and abnormal in 10 cases (3 artifacts,4 ischemia and 3
unknown myocardial infarction scar). Normal stress ejection fraction was 68±
7%, end-diastolic and end-systolic volumes were 72±27 and 23±11 ml. The
effective dose at stress was 0.79±0.08 mSv for men and 1.02±0.07 mSv for
women. The rest activity (average 430 MBq) leads to an additional dose of
3.02 mSv for men and 3.89 mSv for women.
Conclusions: With reduced activities of Tc99m-sestaMIBI, CZT cameras
give high quality imaging. It leads to a decrease of equivocal results and a low
ratio of patients needing an additional rest scan. The effective dose is thus
very low, less or equal to 1 mSv in most cases.
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Background: Midregional pro-Adrenomedulin (MR-proADM) appears to
be a powerful predictor of adverse outcome after AMI when measured 3 to 5
days after symptoms onset.
Objectives: We sought to assess whether (MR-proADM) measured at
admission would correlate with the outcome in ST-segment elevation myocar-
dial infarction patient treated with primary PCI. 
Methods: We measured plasma MR-proADM in 283 consecutive STEMI
patients (74.8% men, mean age 64.2 ± 15 years) immediately after the sheath
insertion and before the primary PCI. We assessed the relation between MR-
proADM and mortality (in-hospital and 1year of follow-up) and compared
them to the prognostic value of troponin I (peak value) and the TIMI risk
Score for STEMI patients.
Results: All cause mortality was 4.5% at discharge and 7.3% at the end of
the follow-up (365 days). The MR-proADM was increased in patients who
died compared with survivors (median 1.27 nmol/l, IQR [0.99 to 3.16 nmol/
l], vs. 0.53 nmol/l, range 0.39 to 0.68 nmol/l], p < 0.0001). 
The areas under the receiver-operating characteristic curve for long-term
survival (one year) for MR-proADM, Troponin I (peak value in μg/l) and
TIMI Risk Score were 0.79 (0.64-0.95) p<0.001, 0.58 (0.49-0.68) p=0.06, and
0.67 (0.55-0.79) p=0.01 respectively. 
Findings were similar for in-hospital mortality 0.77 (0.55-0.98) p=0.002
for MR-proADM. 
Conclusions: Early measurement of MR-proADM during the acute phase
of AMI is a powerful predictor of short and long term mortality in STEMI
patients.
The MR-proADM may represent a clinically useful marker of prognosis
during AMI. 
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Impact of the systematic use of DES on the clinical outcome in diabe-
tic patients
I. Jousten [Orateur], A. Raptis, Jacques Jamart, P. Chenu, V. Dangoisse,
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Background: In November 2003, DES were reimbursed by the belgian
Health Insurance System for diabetic patients, based on their higher restenosis
rate after BMS implantation and improved outcome in randomized trials.
Aim: To assess the impact of the systematic use of DES in diabetic
patients on procedural management and clinical outcome (= stent thrombosis,
TL revascularization and death). 
Methods: We compared procedural data and outcome in consecutive series
of 366 (1.1.2000 1.11.2003) PCI procedures (hospital stays) by BMS versus
276 PCI procedures with at least one DES (1.11.2003 30.6.2006) performed
at our institution.
Results: Outcome data after hospital discharge are based on Kaplan-Meier
survival curves. 
Stent thrombosis includes definite, probable and possible cases.
Conclusion: In our consecutive series, the beneficial effect of systematic
DES implantation on repeat TLR in diabetic patients was less impressive than
expected, based on previous randomized trials. However, the rate of stent
thrombosis was not increased. Overall mortality was not reduced (at 4 y.)
despite better secondary prevention measures. Changes in revascularization
strategies in diabetic patients (indications, procedural) may explain partially
the reduction of the expected benefit by systematic use of DES in routine clin-
ical practice in this single center all-comes registry.
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